Find policies, billing codes, payers, states, and providers
DefenCath (taurolidine/heparin catheter lock) Coverage
Customize your policy alerts
Sign up for Mass General Brigham Health Plan Policy 099 alerts
Get alerted when Policy 099 changes without checking for updates manually.
Monitor payer policy activity
Defines Mass General Brigham Health Plan coverage stance and guidance for DefenCath (taurolidine/heparin catheter lock) for hemodialysis catheter infection prevention across Commercial, MassHealth, and Medicare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for DefenCath (taurolidine/heparin catheter lock)
Commercial and Qualified Health Plan Coverage
Covered when ALL of the following are met:
This designation is the basis for noncoverage and may result in denial of requests for coverage for these members.
MassHealth Coverage Determination
MassHealth members (Mass General Brigham ACO):
Mass General Brigham ACO members use the MassHealth Drug List (Table 66) as the source for coverage criteria.
Medicare Advantage Coverage Determination
Medicare Advantage members:
When CMS provides no guidance for the requested service, the plan's medical policies are used for determinations.
Evidence reviewed indicates that DefenCath reduces catheter-related bloodstream infections (CRBSIs) and may be effective as one preventive option for hemodialysis patients. However, the available data do not demonstrate that DefenCath provides an added clinical benefit when used in addition to chlorhexidine-coated catheter caps, nor do they demonstrate that DefenCath is a cost-effective alternative to chlorhexidine-coated caps.
For Commercial and Qualified Health Plan members, DefenCath is considered experimental and investigational. This determination is the basis for classifying the product as not medically necessary for these member groups and may lead to coverage denial when requested for routine use.
Coding and Billing
| J0911 | Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis) |
Provider Actions, Prior Authorization, and Denial Risk
Authorization status — Experimental/Investigational; check prior auth
DefenCath is listed in this policy as experimental/investigational for Commercial and Qualified Health Plan members; authorization requirements are referenced in the policy header and should be followed per plan-specific prior authorization processes.
- Authorization status fields are present in the policy header — verify plan-specific prior authorization requirements before submitting a request.
Place in therapy — one option, not shown cost‑effective vs chlorhexidine caps
DefenCath is one of several preventive options to reduce catheter‑related bloodstream infections (CRBSIs) for hemodialysis patients but the evidence does not demonstrate added benefit or cost‑effectiveness compared with chlorhexidine‑coated catheter caps. Consider existing catheter infection‑prevention protocols and alternative measures before selecting DefenCath.
- Do not substitute DefenCath as a demonstrated cost‑effective alternative to chlorhexidine‑coated catheter caps; the evidence base does not support superiority or cost‑effectiveness.
- Consider DefenCath only as one tool among multiple preventive strategies for CRBSI.
Coverage determination sources — MassHealth Table 66; CMS guidance for Medicare Advantage
Follow the designated external sources when determining coverage: for MassHealth ACO members, use the MassHealth Drug List (see Table 66: Antibiotics and Anti‑Infectives Injectable); for Medicare Advantage members, follow CMS NCDs/LCDs/LCAs and Medicare manuals when available — if CMS has no guidance, the plan's medical policy is used.
- MassHealth ACO members: use MassHealth Drug List criteria located in Table 66.
- Medicare Advantage members: apply CMS NCDs/LCDs/LCAs and Medicare manuals; if none exist for DefenCath, the plan policy governs.
Denial risk — Experimental/Investigational basis; document thoroughly for appeals
Requests for DefenCath for Commercial and Qualified Health Plan members may be denied because the policy considers the therapy experimental/investigational. If denied, provide clinical rationale, pertinent trial data, and any member‑specific reasons for use in the appeal documentation.
- Denial risk: policy basis — DefenCath is considered experimental/investigational for Commercial and Qualified Health Plan members.
- Appeal guidance: include supporting clinical evidence and justification for why alternatives are unsuitable or ineffective for the individual patient.
Background on DefenCath and Clinical Context
DefenCath is a central venous catheter lock solution composed of taurolidine and heparin intended to reduce rates of catheter-related bloodstream infections (CRBSIs) among patients receiving chronic hemodialysis. Clinical trials, including randomized studies, have shown reductions in infection rates with taurolidine/heparin locks, but interpretation is limited by questions about comparators, baseline infection rates, and combination use with other preventive measures.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.